The Effect of a Mediterranean Intermittent Fasting Diet Compared to Weight-reducing Medication on Liver Fibrosis in People With Type 2 Diabetes and Overweight (MEDFAST-study)

• Status: RECRUITING
• Trial end date: 2027-03-01

Summary

In the Netherlands, there are many people with type 2 diabetes. More than half of these people also have fatty liver. This is a build-up of fat in the liver (steatosis) and can lead to long-term scarring (fibrosis) and even death of the liver. Losing weight can help reduce this. Losing weight can be done with medication such as Mysimba, which is often prescribed to people with type 2 diabetes, but losing weight can also be done with diet. In this study, the investigators want to combine a Mediterranean diet (with lots of vegetables, fruits, whole grain products, nuts and olive oil) with intermittent fasting. In addition participants are not allowed to eat after the evening meal. The investigators will compare this with a group of participants receiving Mysimba, to see if a diet with intermittent fasting might be better for reducing liver steatosis and fibrosis in people with type 2 diabetes.

• Phase: PHASE4

Details

• Lead Sponsor: Carmen Dietvorst
• Treatments: Bupropion; bupropion hydrochloride, naltrexone hydrochoride drug combination; Diet Therapy; Diet, Mediterranean; Naltrexone